Glomerulonephritis
Conditions
Keywords
KP104, Immunoglobulin A Nephropathy, Compliment-mediated Glomerulonephritis, Complement Inhibitor
Brief summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort. Approximately 42 participants with IgAN will be enrolled in 2 stages: Stage 1 will be used to collect safety, immunogenicity, PK, and PD data to select the optimal biologic dose (OBD) of KP104 for IgAN, as well as to preliminarily explore the effect of KP104 on C3G. Stage 2 will be used to collect safety, immunogenicity, PK, PD, and efficacy data at the OBD dose of KP104 for IgAN and C3G. As soon as the OBD for IgAN is determined, eligible participants with C3G will be enrolled and dosed at the OBD for IgAN for a minimum of 48 weeks for weekly maintenance dosing and a minimum of 47 weeks for biweekly maintenance dosing. Approximately 10 participants with C3G will be enrolled.
Interventions
DRUGKP104
Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
Sponsors
Kira Pharmacenticals (US), LLC.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Weight of \>35 kilograms (kg) at Screening * Body mass index (BMI) of \<35 kilograms per square meter (kg/m\^2) * UPCR \>1.0 grams per gram (g/g) by 24-hour urine collection at Screening * Documented diagnosis and clinical status of IgAN or C3G as follows: IgAN: * Diagnosis of IgAN verified by biopsy taken within the past 3 years prior to enrolment. * On stable regimen of angiotensin converting enzyme or angiotensin blocking agents for 12 weeks and/or sodium-glucose cotransporter-2 (SGLT2) inhibitors for 6 weeks at Screening C3G: * Diagnosis of C3G verified by biopsy taken within the past 3 years prior to enrolment. * On stable regimen of angiotensin converting enzyme or angiotensin blocking agents for 12 weeks and/or SGLT2 inhibitors for 6 weeks at Screening * Females of childbearing potential and males must practice effective contraception from Screening until 28 days after the end of study (EOS) visit. * Females of childbearing potential must have a negative pregnancy test at Screening and within 1 day prior to dosing of study drug
Exclusion criteria
* Any clinically significant, poorly controlled underlying illness other than IgAN or C3G, as determined by the investigator * Treatment of any infection with IV (within 30 days of Screening) or oral (within 14 days of Screening) antibiotics, antivirals, or antifungals * History of infections with encapsulated organisms * History of untreated tuberculosis * Positive serology for hepatitis C virus (HCV) ribonucleic acid (RNA) or human immunodeficiency virus (HIV) at Screening * History of bone marrow or stem cell transplantation * Absolute neutrophil count (ANC) \<500 cells per microliter (cells/μL) * eGFR \<30 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula * Presence of crescent formation in \>50 percent (%) of glomeruli assessed on renal biopsy * Nephrotic syndrome defined as presence of substantial proteinuria (\> 3.5 g/24 hours), hypoalbuminemia (\< 30 grams per liter \[g/L\]), and edema/hyperlipidemia. Nephrotic range proteinuria alone is acceptable. * Rapidly progressive glomerulonephritis, defined as a fall in eGFR of \> 30 mL/min/1.73 m\^2 within 24 weeks prior to the Screening Visit * Receiving renal replacement therapy or anticipated to require renal replacement therapy during the duration of the study NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent change from Baseline in 24-hour urinary protein creatinine ratio (UPCR) at Week 24 (C3G) for participants in Stage 2 | Baseline and at Week 24 | The UPCR will be calculated as percent change in protein (Pr)/ Creatinine (Cr). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in estimated glomerular filtration rate (eGFR) at Week 24 (C3G) for participants in Stage 2 | Baseline and at Week 24 | — |
| Number of participants reporting Treatment-Emergent Adverse Events (TEAEs) | Up to 56 Weeks | An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. A TEAE is defined as any AE that started or worsened in severity on or after the first dose of study treatment. |
| Trough concentration (Ctrough) of KP104 at steady state | At Baseline (Day 1), Days 8, 15, 22, 29, 43, 57, 85, 169, 253, 337, 365 and 395 | Blood samples will collected at indicated timepoints to assess Ctrough. |
| Number of participants reporting AEs of Special Interest (AESIs) | Up to 56 Weeks | An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. Number of participants with AESIs including infections and local or systemic administration reactions will be assessed. |
| Maximum concentration (Cmax) of KP104 | At Baseline (Day 1), Days 8, 15, 22, 29, 43, 57, 85, 169, 253, 337, 365 and 395 | Blood samples will collected at indicated timepoints to assess Cmax. |
| Number of participants reporting Treatment-Emergent Serious Adverse Events (TESAEs) | Up to 56 Weeks | A TESAE is defined as a serious AE (SAE) that started or worsened in severity on or after the first dose of study treatment. |
Contacts
Primary ContactStudy Director
Outcome results
None listed